Compare IIIN & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIN | CABA |
|---|---|---|
| Founded | 1953 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.9M | 495.7M |
| IPO Year | 1994 | 2019 |
| Metric | IIIN | CABA |
|---|---|---|
| Price | $30.58 | $3.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 128.7K | ★ 4.7M |
| Earning Date | 04-16-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | ★ 112.12 | 10.26 |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $647,706,000.00 | N/A |
| Revenue This Year | $14.20 | N/A |
| Revenue Next Year | $6.82 | N/A |
| P/E Ratio | $27.09 | ★ N/A |
| Revenue Growth | ★ 22.39 | N/A |
| 52 Week Low | $24.35 | $1.56 |
| 52 Week High | $39.91 | $4.23 |
| Indicator | IIIN | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 69.57 |
| Support Level | $30.49 | $2.58 |
| Resistance Level | $31.04 | $3.67 |
| Average True Range (ATR) | 0.72 | 0.23 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 37.01 | 94.64 |
Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.